Toenail nicotine level as a novel biomarker for lung cancer risk

American Journal of Epidemiology

Volumn 173, Issue 7, 2011, Pages 822-828

  Al Delaimy, Wael K ^a   Willett, Walter C ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cohort studies; lung neoplasms; nails; nicotine; tobacco

Indexed keywords

NICOTINE;

ALKALOID; BIOMARKER; CANCER; HEALTH RISK; HEALTH SURVEY; MENS HEALTH; MULTIVARIATE ANALYSIS; RESPIRATORY DISEASE; SMOKING;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; HEALTH CARE PERSONNEL; HUMAN; LUNG CANCER; MALE; NAIL;

ADULT; AGED; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; HEALTH PERSONNEL; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAILS; NICOTINE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SMOKING; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

UNITED STATES;

NICOTIANA TABACUM;

EID: 79953875341     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq446     Document Type: Article

References (33)

1. Doll R, Peto R. Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Community Health. 1978; 32(4):303-313. (Pubitemid 9067838)
2. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, US Department of Health and Human Services; 2004.
3. US Department of Health and Human Services. Reducing the Health Consequences of Smoking: 25 Years of Progress: A Report of the Surgeon General. Rockville, Maryland: Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, US Department of Health and Human Services, 1989. (DHHS publication (CDC) 89-8411).
4. Patterson F, Benowitz N, Shields P, et al. Individual differences in nicotine intake per cigarette. Cancer Epidemiol Bio-markers Prev. 2003;12(5):468-471. (Pubitemid 36578488)
5. Scherer G. Smoking behaviour and compensation: a review of the literature. Psychopharmacology (Berl). 1999;145(1):1-20. (Pubitemid 29339758)
6. Armstrong B, White E, Saracci R. Principles of Exposure Measurement in Epidemiology. Monographs in Epidemiology and Biostatistics. Oxford: United Kingdom: Oxford University Press; 1992.
7. Dolcini MM, Adler NE, Lee P, et al. An assessment of the validity of adolescent self-reported smoking using three biological indicators. Nicotine Tob Res. 2003;5(4):473-483. (Pubitemid 37081128)
8. Etzel RA. A review of the use of saliva cotinine as a marker of tobacco smoke exposure. Prev Med. 1990;19(2):190-197. (Pubitemid 20227549)
9. Wall MA, Johnson J, Jacob P, et al. Cotinine in the serum, saliva, and urine of nonsmokers, passive smokers, and active smokers. Am J Public Health. 1988;78(6):699-701.
10. Bryant MS, Skipper PL, Tannenbaum SR, et al. Hemoglobin adducts of 4-aminobiphenyl in smokers and nonsmokers. Cancer Res. 1987;47(2):602-608. (Pubitemid 17009633)
11. Schäffler G, Betz C, Richter E. Mass spectrometric analysis of tobacco-specific hemoglobin adducts. Environ Health Per-spect. 1993;99:187-189. (Pubitemid 23174470)
12. Weston A, Caporaso NE, Taghizadeh K, et al. Measurement of 4-aminobiphenyl-hemoglobin adducts in lung cancer cases and controls. Cancer Res. 1991;51(19):5219-5223.
13. Church TR, Anderson KE, Caporaso NE, et al. A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarkers Prev. 2009;18(1):260-266.
14. Yuan JM, Koh WP, Murphy SE, et al. Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. Cancer Res. 2009;69(7):2990-2995.
15. Hecht SS, Carmella SG, Le KA, et al. 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanol and its glucuronides in the urine of infants exposed to environmental tobacco smoke. Cancer Epidemiol Biomarkers Prev. 2006;15(5):988-992. (Pubitemid 43823528)
16. Lubin JH, Caporaso N, Hatsukami DK, et al. The association of a tobacco-specific biomarker and cigarette consumption and its dependence on host characteristics. Cancer Epidemiol Biomarkers Prev. 2007;16(9):1852-1857. (Pubitemid 47450517)
17. Al-Delaimy WK. Hair as a biomarker for exposure to tobacco smoke. Tob Control. 2002;11(3):176-182.
18. Nafstad P, Botten G, Hagen JA, et al. Comparison of three methods for estimating environmental tobacco smoke exposure among children aged between 12 and 36 months. Int J Epidemiol. 1995;24(1):88-94.
19. Wipfli H, Avila-Tang E, Navas-Acien A, et al. Secondhand smoke exposure among women and children: evidence from 31 countries. Am J Public Health. 2008;98(4):672-679. (Pubitemid 351573688)
20. Pichini S, Garcia-Algar O, Muñoz L, et al. Assessment of chronic exposure to cigarette smoke and its change during pregnancy by segmental analysis of maternal hair nicotine. J Expo Anal Environ Epidemiol. 2003;13(2):144-151. (Pubitemid 36566144)
21. Al-Delaimy WK, Willett WC. Measurement of tobacco smoke exposure: comparison of toenail nicotine biomarkers and self-reports. Cancer Epidemiol Biomarkers Prev. 2008;17(5): 1255-1261.
22. Al-Delaimy WK, Mahoney GN, Speizer FE, et al. Toenail nicotine levels as a biomarker of tobacco smoke exposure. Cancer Epidemiol Biomarkers Prev. 2002;11(11):1400-1404. (Pubitemid 35340376)
23. Rimm EB, Stampfer MJ, Colditz GA, et al. Effectiveness of various mailing strategies among nonrespondents in a prospective cohort study. Am J Epidemiol. 1990;131(6): 1068-1071. (Pubitemid 20178628)
24. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. Am J Epidemiol. 1984;119(5):837-839. (Pubitemid 14142821)
25. Mahoney GN, Al-Delaimy W. Measurement of nicotine in hair by reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl. 2001;753(2):179-187. (Pubitemid 32217716)
26. Benowitz NL, Jacob P III, Kozlowski LT, et al. Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide. N Engl J Med. 1986;315(21):1310-1313. (Pubitemid 17030407)
27. Al-Delaimy W, Fraser T, Woodward A. Nicotine in hair of bar and restaurant workers. N Z Med J. 2001;114(1127):80-83. (Pubitemid 32225639)
28. Boffetta P, Clark S, Shen M, et al. Serum cotinine level as predictor of lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1184-1188.
29. Stram DO, Yuan JM, Chan KK, et al. Beta-cryptoxanthin and lung cancer in Shanghai, China-an examination of potential confounding with cigarette smoking using urinary cotinine as a biomarker for true tobacco exposure. Nutr Cancer. 2007; 57(2):123-129. (Pubitemid 47080083)
30. Al-Delaimy WK, Crane J, Woodward A. Is the hair nicotine level a more accurate biomarker of environmental tobacco smoke exposure than urine cotinine? J Epidemiol Community Health. 2002;56(1):66-71. (Pubitemid 34076272)
31. Al-Delaimy WK, Stampfer MJ, Manson JE, et al. Toenail nicotine levels as predictors of coronary heart disease among women. Am J Epidemiol. 2008;167(11):1342-1348. (Pubitemid 351770555)
32. Stepanov I, Hecht SS, Lindgren B, et al. Relationship of human toenail nicotine, cotinine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol to levels of these biomarkers in plasma and urine. Cancer Epidemiol Biomarkers Prev. 2007;16(7): 1382-1386. (Pubitemid 47076867)
33. Nicotine gum a boon that the experts say should be used more. New York Times. January 28, 1988. (http://www.nytimes.com/ 1988/01/28/us/health-therapy- for-smokers-nicotine-gum-boon-that-experts-say-should-be-used.html).